Neovacs News - ALNEV

NEOVACS STRENGTHENS ITS FINANCIAL STRUCTURE: ISSUANCE OF "ORNANE" FOR A MAXIMUM AMOUNT OF €10M, WITHOUT STOCK SUBSCRIPTION...

NEOVACS STRENGTHENS ITS FINANCIAL STRUCTURE: ISSUANCE OF "ORNANE" FOR A MAXIMUM AMOUNT OF €10M, WITHOUT STOCK SUBSCRIPTION WARRANTS...

Neovacs reports full-year 2018 Financial results and provides corporate update

Neovacs reports full-year 2018 Financial results and provides corporate update RESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS...

Neovacs to present the preclinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid at Keystone Congress

Neovacs to present the preclinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid at Keystone Congress PRESS RELEASE ·...

Néovacs annonce deux nominations au sein de son comité exécutif

Néovacs annonce deux nominations au sein de son comité exécutif COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE...

Néovacs : Agenda financier 2019

Néovacs : Agenda financier 2019 COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE AGENDA FINANCIER 2019 Paris et Boston...

Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris

Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris NEOVACS TO HOST...

Neovacs announces its clinical advisory board meeting to design the Phase III Study for IFNalpha Kinoide in lupus - Paris Feb...

Neovacs announces its clinical advisory board meeting to design the Phase III Study for IFNalpha Kinoide in lupus - Paris February 11th...

Neovacs to present full results from the Phase IIb IFNalpha Kinoid clinical study at the 13th International Lupus Congress

Neovacs to present full results from the Phase IIb IFNalpha Kinoid clinical study at the 13th International Lupus Congress PRESS RELEASE ·...

NÉOVACS REÇOIT UN FINANCEMENT DE L'ANR - L'AGENCE NATIONALE DE LA RECHERCHE - POUR LE DÉVELOPPEMENT DE L'IL-4/IL-13 KINOÏ...

COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE · COMMUNIQUÉ DE PRESSE NÉOVACS REÇOIT UN FINANCEMENT DE L'ANR - L'AGENCE NATIONALE DE LA...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Neovacs (ALNEV)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ALNEV News

NEOVACS STRENGTHENS ITS FINANCIAL STRUCTURE: ISSUANCE OF "ORNANE" FOR A MAXIMUM AMOUNT OF €10M, WITHOUT STOCK SUBSCRIPTION...

Neovacs reports full-year 2018 Financial results and provides corporate update

Neovacs to present the preclinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid at Keystone Congress

Néovacs annonce deux nominations au sein de son comité exécutif

Néovacs : Agenda financier 2019

Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris

Neovacs announces its clinical advisory board meeting to design the Phase III Study for IFNalpha Kinoide in lupus - Paris Feb...

Neovacs to present full results from the Phase IIb IFNalpha Kinoid clinical study at the 13th International Lupus Congress

NÉOVACS REÇOIT UN FINANCEMENT DE L'ANR - L'AGENCE NATIONALE DE LA RECHERCHE - POUR LE DÉVELOPPEMENT DE L'IL-4/IL-13 KINOÏ...

ALNEV Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Neovacs (ALNEV) News

Neovacs (ALNEV)

Empower your portfolio: Real-time discussions and actionable trading ideas.

ALNEV News

NEOVACS STRENGTHENS ITS FINANCIAL STRUCTURE: ISSUANCE OF "ORNANE" FOR A MAXIMUM AMOUNT OF €10M, WITHOUT STOCK SUBSCRIPTION...

Neovacs reports full-year 2018 Financial results and provides corporate update

Neovacs to present the preclinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid at Keystone Congress

Néovacs annonce deux nominations au sein de son comité exécutif

Néovacs : Agenda financier 2019

Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris

Neovacs announces its clinical advisory board meeting to design the Phase III Study for IFNalpha Kinoide in lupus - Paris Feb...

Neovacs to present full results from the Phase IIb IFNalpha Kinoid clinical study at the 13th International Lupus Congress

NÉOVACS REÇOIT UN FINANCEMENT DE L'ANR - L'AGENCE NATIONALE DE LA RECHERCHE - POUR LE DÉVELOPPEMENT DE L'IL-4/IL-13 KINOÏ...

ALNEV Discussion

Your Recent History